BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35126914)

  • 41. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
    Cao S; Yu Y; Chen S; Lei D; Wang S; Pan X; Peng J
    Biochem Biophys Res Commun; 2017 Jan; 482(4):536-541. PubMed ID: 27847320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies.
    Wang X; Liu X; Huang J; Liu C; Li H; Wang C; Hong Q; Lei Y; Xia J; Yu Z; Dong R; Xu J; Tu Z; Duan C; Li S; Lu T; Tang W; Chen Y
    Eur J Med Chem; 2022 Aug; 238():114461. PubMed ID: 35605362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
    Lyle L; Daver N
    Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Yokoyama A
    Apoptosis; 2009 Sep; 14(9):1108-20. PubMed ID: 19548087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia.
    Eriksson A; Kalushkova A; Jarvius M; Hilhorst R; Rickardson L; Kultima HG; de Wijn R; Hovestad L; Fryknäs M; Öberg F; Larsson R; Parrow V; Höglund M
    Biochem Pharmacol; 2014 Jan; 87(2):284-91. PubMed ID: 24200998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
    Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
    Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.
    Song JH; Kim SH; Kim HJ; Hwang SY; Kim TS
    Int J Oncol; 2008 Apr; 32(4):931-6. PubMed ID: 18360721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal AraC-Cytotoxicity to AML Cells Requires ERK5 Activity.
    Zheng R; Studzinski GP
    J Cell Biochem; 2017 Jun; 118(6):1583-1589. PubMed ID: 27922189
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
    Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia.
    Hege Hurrish K; Qiao X; Li X; Su Y; Carter J; Ma J; Kalpage HA; Hüttemann M; Edwards H; Wang G; Kim S; Dombkowski A; Bao X; Li J; Taub JW; Ge Y
    Biochem Pharmacol; 2022 Nov; 205():115283. PubMed ID: 36208684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
    Nishi R; Shigemi H; Negoro E; Okura M; Hosono N; Yamauchi T
    BMC Cancer; 2020 Oct; 20(1):984. PubMed ID: 33046037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.
    Kelly KR; Nawrocki ST; Espitia CM; Zhang M; Yang JJ; Padmanabhan S; Ecsedy J; Giles FJ; Carew JS
    Int J Cancer; 2012 Dec; 131(11):2693-703. PubMed ID: 22488249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
    Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
    Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
    Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
    Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
    Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
    Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
    Beauchamp EM; Abedin SM; Radecki SG; Fischietti M; Arslan AD; Blyth GT; Yang A; Lantz C; Nelson A; Goo YA; Akpan I; Eklund EA; Frankfurt O; Fish EN; Thomas PM; Altman JK; Platanias LC
    Blood; 2019 Mar; 133(11):1171-1185. PubMed ID: 30587525
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
    Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
    Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
    Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
    Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
    Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
    Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
    Boiko S; Proia T; San Martin M; Gregory GP; Wu MM; Aryal N; Hattersley M; Shao W; Saeh JC; Fawell SE; Johnstone RW; Drew L; Cidado J
    Blood; 2021 May; 137(21):2947-2957. PubMed ID: 33259592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.